Welcome to our dedicated page for Castle Biosciences news (Ticker: CSTL), a resource for investors and traders seeking the latest updates and insights on Castle Biosciences stock.
Castle Biosciences, Inc. (Nasdaq: CSTL) is a diagnostics company focused on molecular tests that guide patient care in dermatologic and gastroenterological disease. The CSTL news feed highlights company announcements, clinical data, financial results and corporate updates that shape how investors and clinicians view its role in precision medicine.
Readers can follow news on Castle’s core test portfolio, including DecisionDx-Melanoma for cutaneous melanoma, TissueCypher Barrett’s Esophagus, DecisionDx-SCC for high-risk cutaneous squamous cell carcinoma, MyPath Melanoma and its suite of tests for uveal melanoma such as DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq. Coverage also includes updates on AdvanceAD-Tx, the company’s gene expression profile test designed to guide systemic treatment decisions in moderate-to-severe atopic dermatitis.
In addition to product and clinical evidence updates, CSTL news items feature quarterly and annual financial results, test volume trends for core revenue drivers, and guidance ranges reported in earnings releases. Regulatory and corporate governance developments, such as bylaw amendments disclosed in Form 8-K filings, as well as participation in healthcare and investor conferences, are also common topics.
Because Castle Biosciences emphasizes rigorous clinical validation, many news releases center on new studies, meta-analyses and expert consensus papers that evaluate the performance of its tests in real-world and prospective cohorts. These articles provide insight into how DecisionDx-Melanoma, TissueCypher and other assays are being integrated into clinical decision-making.
For investors, clinicians and researchers tracking CSTL, this news page offers a centralized view of earnings announcements, product launches, reimbursement developments, clinical data presentations and corporate events related to Castle Biosciences’ molecular diagnostics business.
Castle Biosciences, Inc. (CSTL) will release its financial results for Q2 and six months ending June 30, 2022, after market close on August 8, 2022. A conference call to discuss the results is scheduled for 4:30 p.m. Eastern Time on the same day. The webcast will be available on the company's Investor Relations page. Castle specializes in diagnostics, focusing on innovative tests for skin cancers and other conditions, with ongoing research in new test developments.
Castle Biosciences (NASDAQ: CSTL) announces a milestone of over 100,000 orders for its DecisionDx-Melanoma test. This test assists in guiding treatment decisions for patients diagnosed with cutaneous melanoma. Since its launch, more than 105,000 tests have been ordered by over 10,200 providers. The test's clinical utility is backed by over 35 peer-reviewed publications and has shown a 27% improvement in melanoma-specific survival in recent studies. The company's commitment to transforming patient care continues to drive its innovations in diagnostics.
Castle Biosciences (NASDAQ: CSTL) announced a presentation on its DecisionDx-Melanoma test at the 2022 American Academy of Dermatology Innovation Academy in Vancouver, Canada, from July 21-24. The test assesses individual risk for sentinel lymph node positivity and melanoma recurrence using a 31-gene expression profile. Dr. Aaron Farberg will discuss how this test aids in decision-making and improves patient outcomes. Over 97,288 tests have been ordered as of March 31, 2022, showing significant engagement and validation in melanoma management.
Summary not available.
Castle Biosciences (Nasdaq: CSTL) reported findings from a study on uveal melanoma patients' attitudes towards prognostic testing with DecisionDx-UM. The research, presented at the 20th International Society of Ocular Oncology congress, showed that 90% of 177 surveyed patients desired prognostic information at diagnosis. Notably, there was no significant difference in decision regret among varying risk classifications (Class 1A, 1B, Class 2). Patients appreciated the insights gained from the test, including better understanding of their disease and personalized treatment options.
Castle Biosciences (CSTL) announced new findings demonstrating that its tests, DecisionDx-Melanoma and DecisionDx-SCC, can significantly improve patient management in skin cancer treatment. A pooled analysis revealed that DecisionDx-Melanoma effectively identifies high-risk melanoma patients among traditionally low-risk groups, with a notable difference in 3-year recurrence-free survival rates (75.9% vs. 97.7%). Additionally, a survey of dermatologic clinicians indicated that DecisionDx-SCC results can lead to risk-aligned treatment adjustments. The lab workflow for MyPath Melanoma and DecisionDx DiffDx-Melanoma achieved over 99% reporting of actionable results.
Castle Biosciences (CSTL) has partnered with Oregon Health & Science University in the War on Melanoma, a public health initiative aimed at early detection and prevention of melanoma. This collaboration supports education and awareness programs, including the Start Seeing Melanoma campaign and the Skin Crew, which involves professionals identifying potential skin cancer signs. Castle emphasizes the importance of early diagnosis in improving patient outcomes. The company continues to focus on innovative tests to enhance patient care and disease management.
Castle Biosciences announced the results of a recent poster presentation regarding its DecisionDx®-Melanoma test at the 2022 Fall Clinical Dermatology Conference. The study surveyed 120 melanoma patients and revealed that 90% wanted prognostic information at diagnosis. The findings indicate that patients value the insights provided by the DecisionDx-Melanoma test, with over 90% finding it useful for understanding their condition. The test has been ordered 97,288 times, suggesting its growing adoption in clinical settings.
Castle Biosciences (Nasdaq: CSTL) announces a presentation at the JMP Securities Life Sciences Conference on June 16, 2022, by CEO Derek Maetzold and CFO Frank Stokes at 10:30 a.m. Eastern time. A live audio webcast will be accessible on Castle's website, with a replay available for two weeks post-event. The company focuses on innovative diagnostic tests for various cancers and health conditions, aiming to enhance patient care through advanced solutions. For details, visit CastleBiosciences.com.
Castle Biosciences has been awarded the 'Best New Technology Solution – Dermatology' in the MedTech Breakthrough Awards for its DecisionDx®-Melanoma gene expression profile test. This award recognizes Castle's innovation in predicting the risk of metastasis and recurrence in patients with invasive cutaneous melanoma. The DecisionDx-Melanoma test combines clinical factors with tumor biology, providing personalized treatment insights. In 2021, Castle's tests also received accolades in oncology, showcasing its commitment to improving patient care through advanced diagnostics.